Print

Novo Nordisk A/S (NVO) Study: Degludec Cuts Night-Time Hypoglycemia Risk  
10/3/2012 7:55:48 AM

A new study shows that insulin degludec, an investigational diabetes drug developed by the world's largest insulin maker, Novo Nordisk A/S (NOVO-B.KO), sharply cuts diabetes patients' risk of incurring night-time hypoglycaemia compared with traditional insulin, the company said Tuesday. Compared with insulin glargine, patients had a 43% lower rate of night-time hypoglycaemia, according to the two-year study, which investigated 1,030 patients with type 2 diabetes. The patients, who hadn't previously been treated with insulin, also had a significantly lower rate of severe hypoglycaemia, according to the data, which were presented at the Annual Meeting of the European Association for the Study of Diabetes in Berlin.
//-->